Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Recent analyst ratings and news for three high-yielding healthcare stocks reveal mixed sentiment: Pfizer (PFE) received a maintained Neutral rating from UBS with an increased price target to $25, while Guggenheim reiterated a Buy rating; Merck & Co. (MRK) was downgraded by Citigroup to Neutral with a reduced price target of $84, though Guggenheim reiterated a Buy rating following FDA approval of Keytruda; DENTSPLY SIRONA (XRAY) had its price target lowered by UBS while Mizuho also lowered their price target, alongside pricing a $550 million junior subordinated notes offering.

Analysis

The healthcare sector presents several high-dividend-yielding stocks, attracting investor focus amid market turbulence. Pfizer (PFE), offering a substantial 7.17% dividend yield, shows mixed analyst perspectives: UBS analyst Trung Huynh (71% accuracy) maintained a Neutral rating, increasing the price target from $24 to $25 on April 30, 2025, while Guggenheim's Vamil Divan (74% accuracy) reiterated a Buy rating on March 18, 2025. A recent development for Pfizer is the New Drug Application submission to the FDA with its partner Arvinas, Inc. on June 6. Merck & Co., Inc. (MRK), with a 4.14% dividend yield, faces divergent analyst outlooks: Citigroup's Andrew Baum (70% accuracy) downgraded the stock from Buy to Neutral and cut the price target from $115 to $84 on May 14, 2025, contrasting with Vamil Divan of Guggenheim (74% accuracy) who reiterated a Buy rating with a $115 price target on April 17, 2025. This occurred as Merck received FDA approval for Keytruda in a new indication for head and neck squamous cell carcinoma. DENTSPLY SIRONA Inc. (XRAY), yielding 4.16%, experienced price target reductions: UBS analyst Kevin Caliendo (71% accuracy) maintained a Buy rating but lowered the target from $27 to $25 on May 9, 2025, and Mizuho's Steven Valiquette (62% accuracy) maintained a Neutral rating while reducing the target from $21 to $18 on March 13, 2025, alongside Dentsply Sirona pricing a $550 million junior subordinated notes offering on June 5. The overall sentiment signals are mixed for these developments, with a general sentiment score of 0.15, indicative of the varied analyst outlooks and specific company events.

Key Decisions for Investors

• Investors attracted to high dividend yields in the healthcare sector should scrutinize the divergent analyst ratings for Pfizer, Merck, and Dentsply Sirona, particularly noting price target adjustments and the accuracy rates of the analysts.
• Key catalysts to monitor include the FDA review outcome for Pfizer's partnered New Drug Application, the commercial uptake and market impact of Merck's recently approved Keytruda indication, and the strategic implications of Dentsply Sirona's $550 million debt offering on its financial health and growth prospects.
• Given the conflicting signals, including per-ticker sentiments ranging from slightly negative for XRAY (-0.2) to moderately positive for MRK (0.6), a cautious approach is warranted, involving a thorough assessment of each company's fundamentals against the backdrop of these analyst actions and news before adjusting positions.